Compare SVRN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVRN | KTTA |
|---|---|---|
| Founded | 2021 | 2020 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 18.1M |
| IPO Year | 2021 | 2021 |
| Metric | SVRN | KTTA |
|---|---|---|
| Price | $52.06 | $0.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 204.3K | 194.8K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $486,559.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3130.37 |
| 52 Week Low | $0.16 | $0.28 |
| 52 Week High | $52.00 | $2.06 |
| Indicator | SVRN | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 93.27 | 42.21 |
| Support Level | $4.03 | $0.48 |
| Resistance Level | N/A | $0.52 |
| Average True Range (ATR) | 5.34 | 0.04 |
| MACD | 4.13 | -0.01 |
| Stochastic Oscillator | 87.01 | 27.91 |
Svrn Inc operates in the digital asset and blockchain sector, with a focus on the NEAR Protocol. Its activities include managing a digital asset treasury comprising NEAR, promoting commercial adoption of NEAR-based products, and backing, building, and acquiring ventures that serve its mission.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.